Hormones — ER-α and Androgens
What withaferin A appears to do in ER-positive breast cancer, and why older hormone-based cautions need updating.
Ashwagandha and WFA have often been treated cautiously in ER-positive breast cancer because of hormone concerns. The newer mechanistic picture is more specific than the older blanket “avoid” rule.
Where the original concern came from
The older concern followed an indirect chain:
Small studies in men suggested Ashwagandha could raise testosterone.
Testosterone can convert to oestradiol via aromatase.
Therefore Ashwagandha was treated as potentially unsafe in ER-positive disease.
This logic had major limits. It was not based on women with ER-positive breast cancer, did not isolate WFA, and predated modern work on androgen receptor biology in ER+ disease.
What WFA does to ER-α
In ER-positive breast cancer cell models, WFA has been shown to:
Reduce ER-α protein levels substantially within 24 hours.
Deplete nuclear ER-α.
Suppress oestradiol-driven gene transcription.
Inhibit ER-dependent proliferation.
Increase ER-β, the receptor isoform linked to anti-proliferative signalling.
Mechanistically, this involves both transcriptional repression of ER-α mRNA and proteasome-dependent loss of ER-α protein. This is not neutral modulation; it is direct ER-α suppression.
Does ER-α rebound above baseline if WFA is stopped?
Current mechanistic work does not show an overshoot or “rebound-above-baseline” effect.
ER-α falls during WFA exposure and then trends back toward its previous baseline once WFA is removed. That still leaves uncertainty at the clinical level, but there is no evidence that pausing WFA leaves ER-positive disease worse than baseline in ER-α expression terms.
Androgen receptor in ER-positive breast cancer
Modern data have also shifted how AR is viewed in ER+ disease.
In ER-positive breast cancer, androgen receptor signalling is now understood as tumour-suppressive rather than tumour-promoting in many contexts. AR activation can displace ER from key genomic sites and repress ER-driven cell-cycle programmes.
That matters because even if some Ashwagandha products modestly altered androgen tone, the old assumption that “more androgen automatically means more ER+ risk” is no longer a strong mechanistic default inside established ER+ tumours.
Practical interpretation
The most reasonable take-home points are:
The old blanket avoidance rule was based on extrapolation, not on direct evidence of harm in women with ER-positive breast cancer.
WFA itself appears to lower ER-α signalling in ER-positive breast cancer models.
Modern AR biology weakens the earlier hormone-fear argument further.
None of this makes WFA a replacement for standard endocrine therapy. It supports viewing WFA as a potential adjunctive ER-modulating compound, rather than an inherently contraindicated one, when used thoughtfully and with monitoring.
What still remains unknown
Important gaps remain:
No clinical trials define WFA as a stand-alone endocrine strategy.
Long-term endocrine outcome data in women using high-potency WFA are absent.
Treatment decisions about aromatase inhibitors, SERDs, or ovarian suppression should still follow established guideline-level evidence.
Bottom line
The mechanistic data support a more nuanced position than older cautionary summaries. In the settings that matter most for ER-positive breast cancer, WFA looks anti-ER-α rather than oestrogenic, and AR signalling looks more like an ally than an automatic threat.
Key references
Sehdev V. et al. — direct ER-α suppression and ER-β increase by WFA.
https://pmc.ncbi.nlm.nih.gov/articles/PMC3129407/
Hahm E. R. et al. — proteasome-linked ER-α down-regulation and RET effects.
https://pmc.ncbi.nlm.nih.gov/articles/PMC3198756/
Stan S. D. et al. — WFA-induced apoptosis in ER+ and ER− breast cancer cells.
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0023354
Hickey T. E. et al. — AR is a tumour suppressor in ER+ breast cancer.
https://pubmed.ncbi.nlm.nih.gov/33462444/
Garvan summary:
https://publications.garvan.org.au/research/publications/15835
NHMRC — broader sex-hormone context in breast cancer.
https://www.nhmrc.gov.au/about-us/news-centre/unlocking-secrets-sex-hormones-breast-cancer
Clinical commentary on Ashwagandha in breast cancer.
Source: Maharjan S. et al., “Keeping abreast about ashwagandha in breast cancer,” Current Problems in Cancer.
https://pubmed.ncbi.nlm.nih.gov/33359916/
Memorial Sloan Kettering Cancer Center Ashwagandha monograph:
https://www.mskcc.org/cancer-care/integrative-medicine/herbs/ashwagandha
Access and availability:
Source: MCS Formulas, “Withaferin A Pro Liposomal.”
50 mg WFA per capsule. Available via healthcare professional request.
https://www.mcsformulas.com/vitamins-supplements/withaferin-a-pro-liposomal/ref/14